Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gatipotuzumab - Glycotope

Drug Profile

Gatipotuzumab - Glycotope

Alternative Names: Anti-TA-MUC1 monoclonal antibody - Glycotope; GlycoOptimised IgG1 antibody - Glycotope; GT-MAB 2.5-GEX™; PankoMab; PankoMab-GEX; Trifunctional antibody - Glycotope

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NEMOD Biotherapeutics [CEASED]
  • Developer Glycotope
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 25 Mar 2019 Glycotope initiates enrolment in the expansion trial of phase Ib GATTO study for Solid tumours
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours in Switzerland (IV, Infusion)
  • 02 Nov 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Spain, Germany (IV) (NCT03360734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top